Intra‑hepatic Cholestasis of Pregnancy - Symptoms, Causes, Treatment & Prevention

```html

Overview

Intra‑hepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs only during pregnancy. It is characterized by impaired bile flow within the liver, leading to a buildup of bile acids in the maternal bloodstream. The condition usually appears in the second or third trimester and resolves shortly after delivery.

Who it affects: ICP can affect any pregnant woman, but it is more common in:

• Women of South Asian, Hispanic, or Scandinavian ancestry.
• Multiparous women (those who have been pregnant before).
• Women with a personal or family history of ICP.
• Women with certain underlying liver disorders (e.g., hepatitis C, gallstones).

Prevalence: Worldwide rates range from 0.2% to 2% of pregnancies, with higher frequencies reported in Chile (up to 5%), Norway (≈1.5%), and India (≈1%). The incidence appears to be rising, possibly due to increased awareness and better diagnostic testing.

Symptoms

ICP primarily causes pruritus (itching) and biochemical changes. The symptom profile can vary from mild to severe.

• Intense itching – Often described as a burning or tingling sensation, typically on the palms of the hands, soles of the feet, and under the arms. It usually worsens at night.
• Jaundice – Yellowing of the skin or whites of the eyes; seen in ~10‑15% of cases.
• Dark urine – Concentrated urine due to excess bilirubin.
• Pale stools – Result of reduced bile pigment reaching the intestines.
• Fatigue or malaise – Generalized tiredness may accompany itching.
• Right‑upper‑quadrant abdominal discomfort – Less common, but some women report a vague ache.
• Elevated serum bile acids – Not a symptom the patient feels, but a key diagnostic hallmark.

Causes and Risk Factors

The exact cause is multifactorial, involving hormonal, genetic, and environmental components.

Hormonal factors

Estrogen and progesterone increase dramatically during pregnancy. In susceptible women, these hormones can impair the transport proteins that move bile acids out of liver cells, leading to cholestasis.

Genetic predisposition

Mutations in genes encoding bile‑acid transporters (e.g., ABCB4, ABCC2, ATP8B1) have been identified in families with recurrent ICP. A positive family history raises the odds of development by up to three‑fold.

Other risk factors

• Previous episode of ICP.
• Multiple gestation (twins or more).
• Pre‑existing liver disease (e.g., hepatitis C, primary biliary cholangitis).
• Maternal age >35 years.
• Use of oral contraceptives before pregnancy (some data suggest a lingering effect).
• Geographic location with higher baseline biliary disease prevalence.

Diagnosis

ICP is a diagnosis of exclusion—other liver or dermatologic conditions must be ruled out.

Step‑by‑step diagnostic approach

1. Clinical assessment: Detailed history focusing on itch pattern, timing, and any accompanying jaundice.
2. Laboratory tests:
   • Serum bile acid level – The gold‑standard test. A fasting level ≥10 µmol/L is diagnostic; levels >40 µmol/L are associated with higher fetal risk.
   • Liver function panel – Typically shows elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST); alkaline phosphatase may rise due to pregnancy.
   • Bilirubin – May be modestly elevated if jaundice is present.
3. Ultrasound – Performed to exclude gallstones, biliary obstruction, or hepatic lesions.
4. Additional labs (if indicated):
   • Viral hepatitis serologies.
   • Autoimmune markers (ANA, anti‑mitochondrial antibodies) if autoimmune hepatitis is suspected.

Because bile‑acid levels can fluctuate, most clinicians repeat the measurement if the first result is borderline (10‑14 µmol/L) and symptoms persist.

Treatment Options

Management aims to relieve maternal symptoms, reduce serum bile‑acid concentrations, and minimize fetal complications.

Medications

• Ursodeoxycholic acid (UDCA) – First‑line therapy. Typical dose: 10‑15 mg/kg/day divided into 2–3 doses. UDCA improves itching, normalizes liver enzymes, and lowers bile‑acid levels in >80% of women (Cochrane Review 2021).
• Rifampicin – Considered when UDCA is insufficient. Dose: 300 mg daily, increased up to 600 mg if needed; monitor liver enzymes.
• Antihistamines – Helpful for nighttime itching but do not affect bile‑acid levels.
• Vitamin K – Occasionally given if prolonged prothrombin time is noted.

Procedural / Monitoring Strategies

• Fetal surveillance – Non‑stress tests (NST) or biophysical profiles twice weekly after bile‑acid levels exceed 40 µmol/L.
• Early delivery – Many obstetricians recommend induction at 37 weeks for mild disease and 36 weeks for severe disease (bile acids >100 µmol/L) to reduce stillbirth risk.
• Post‑delivery follow‑up – Bile‑acid levels and liver enzymes should be rechecked 2–4 weeks postpartum; most women recover completely.

Lifestyle changes

• Consume a low‑fat, high‑fiber diet (fat slows bile‑acid clearance).
• Stay well‑hydrated; aim for ≥2 L of water daily.
• Avoid hot showers or baths that can intensify itching; use cool compresses instead.
• Wear loose, breathable clothing and use mild, fragrance‑free soaps.

Living with Intra‑hepatic Cholestasis of Pregnancy

While ICP can be unsettling, many women lead normal daily lives with proper management.

Practical tips

• Medication adherence – Take UDCA with food; set daily reminders.
• Symptom diary – Record itch intensity, timing, and any new symptoms; share with your provider.
• Sleep hygiene – Use cool pillows, keep bedroom temperature low, and consider antihistamines at night if itching disrupts sleep.
• Skin care – Apply 1% hydrocortisone cream or calamine lotion to soothe localized itching.
• Support network – Engage partners, family, or support groups; emotional stress can exacerbate itching.

Work and travel

Most women can continue working if symptoms are controlled. When traveling, carry medication, a copy of recent lab results, and a letter from your obstetrician outlining the condition and any required monitoring.

Prevention

Because ICP is closely linked to genetics and pregnancy‑related hormones, there is no guaranteed way to prevent it. However, some strategies may lower risk for a future pregnancy:

• Maintain a healthy pre‑conception weight; obesity is associated with higher bile‑acid synthesis.
• Screen for and treat chronic liver disease before conception.
• If you have a personal or familial history of ICP, discuss prophylactic UDCA with your obstetrician early in pregnancy.
• Limit exposure to hepatotoxic substances (e.g., alcohol, certain herbal supplements).

Complications

If left untreated or poorly controlled, ICP can affect both mother and baby.

Maternal complications

• Severe pruritus leading to sleep deprivation and reduced quality of life.
• Vitamin K deficiency → increased bleeding risk during delivery.
• Potential progression to acute fatty liver of pregnancy (rare).

Fetal and neonatal complications

• Preterm birth – Often iatrogenic due to early induction.
• Intrauterine growth restriction (IUGR).
• Fetal distress – Abnormal heart‑rate patterns related to high bile‑acid levels.
• Stillbirth – The most serious risk; studies show a 0.5‑2 % risk, rising sharply when serum bile acids exceed 100 µmol/L (NIH, 2022).
• Neonatal respiratory distress syndrome – May be more common in infants delivered early.

When to Seek Emergency Care

References

• Mayo Clinic. Intrahepatic Cholestasis of Pregnancy. Accessed June 2026.
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 248. 2023.
• Cochrane Database of Systematic Reviews. Ursodeoxycholic acid for intra‑hepatic cholestasis of pregnancy. 2021.
• National Institutes of Health (NIH). Maternal and fetal outcomes in ICP. 2022.
• World Health Organization. Guidelines on management of pregnancy‑related liver disease. 2023.

```